Nutriband Inc. (NASDAQ:NTRB) Sees Large Decrease in Short Interest

Nutriband Inc. (NASDAQ:NTRB) was the recipient of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 2,400 shares, a decrease of 61.9% from the February 29th total of 6,300 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average trading volume of 16,100 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Nutriband

Several hedge funds and other institutional investors have recently bought and sold shares of NTRB. Vanguard Group Inc. grew its position in shares of Nutriband by 10.4% in the 3rd quarter. Vanguard Group Inc. now owns 85,224 shares of the company’s stock worth $217,000 after acquiring an additional 8,028 shares in the last quarter. AlphaQ Advisors LLC acquired a new position in Nutriband in the fourth quarter worth $63,000. Finally, State Street Corp increased its stake in Nutriband by 16.7% during the third quarter. State Street Corp now owns 17,266 shares of the company’s stock valued at $62,000 after purchasing an additional 2,466 shares during the last quarter. 19.70% of the stock is owned by institutional investors.

Nutriband Stock Up 11.6 %

Shares of NTRB traded up $0.47 during midday trading on Thursday, hitting $4.52. The company had a trading volume of 631,244 shares, compared to its average volume of 34,731. The company has a quick ratio of 2.54, a current ratio of 2.79 and a debt-to-equity ratio of 0.37. Nutriband has a 52 week low of $1.53 and a 52 week high of $5.93. The company’s 50 day moving average price is $2.62 and its 200 day moving average price is $2.52. The stock has a market cap of $35.39 million, a price-to-earnings ratio of -6.75 and a beta of 0.72.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.